1. Home
  2. PLUG vs BLLN Comparison

PLUG vs BLLN Comparison

Compare PLUG & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plug Power Inc.

PLUG

Plug Power Inc.

HOLD

Current Price

$2.32

Market Cap

2.9B

Sector

Energy

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$80.12

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLUG
BLLN
Founded
1997
2016
Country
United States
United States
Employees
N/A
713
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.5B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
PLUG
BLLN
Price
$2.32
$80.12
Analyst Decision
Hold
Buy
Analyst Count
13
7
Target Price
$2.09
★ $129.57
AVG Volume (30 Days)
★ 79.4M
318.7K
Earning Date
03-02-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 47.01
N/A
EPS
N/A
★ N/A
Revenue
★ $709,919,000.00
N/A
Revenue This Year
$32.17
$45.89
Revenue Next Year
$14.99
$30.17
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 12.90
N/A
52 Week Low
$0.69
$61.96
52 Week High
$4.58
$138.70

Technical Indicators

Market Signals
Indicator
PLUG
BLLN
Relative Strength Index (RSI) 56.04 54.69
Support Level $2.12 $63.98
Resistance Level $2.54 $86.01
Average True Range (ATR) 0.17 5.61
MACD 0.02 1.30
Stochastic Oscillator 58.89 75.47

Price Performance

Historical Comparison
PLUG
BLLN

About PLUG Plug Power Inc.

Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: